Allergy Therapeutics's total assets for Q4 2023 were £64.83M, a decrease of -6.15% from the previous quarter. GB:AGY total liabilities were £61.12M for the fiscal quarter, a 43.42% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.